GnRH analogue for chemotherapy-induced ovarian damage: too early to say?
Peccatori
Fedro
F
Demeestere
Isabelle
I
D000230:Adenocarcinoma / Q000188:drug therapy / Q000601:surgery; D000328:Adult; D000568:Amenorrhea / Q000139:chemically induced / Q000517:prevention & control; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000188:drug therapy / Q000601:surgery; D004958:Estradiol / Q000097:blood; D005260:Female; D005300:Fertility Agents, Female / Q000008:administration & dosage*; D043373:Follicle Stimulating Hormone, Human / Q000097:blood; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists*; D017273:Goserelin / Q000008:administration & dosage*; D006801:Humans; D007247:Infertility, Female / Q000139:chemically induced / Q000503:physiopathology / Q000517:prevention & control*; D007986:Luteinizing Hormone / Q000097:blood; D008197:Lymph Node Excision; D008408:Mastectomy; D008598:Menstruation / Q000187:drug effects; D010053:Ovary / Q000187:drug effects* / Q000503:physiopathology; D010060:Ovulation / Q000187:drug effects; D016649:Primary Ovarian Insufficiency / Q000139:chemically induced / Q000517:prevention & control
D005300:Fertility Agents, Female; D043373:Follicle Stimulating Hormone, Human; D017273:Goserelin; D007987:Gonadotropin-Releasing Hormone; D004958:Estradiol; D007986:Luteinizing Hormone